News & Press Releases
SET Announcements
Notification convening date of the Public Presentation
Read the full announcement on the SET website ↗Report on the results of the Exercise of XBIO-W8 (F53-5) (Revised)
Read the full announcement on the SET website ↗Financial Transaction with Risk to the Financial Position and Operating Performance and Operating Result and Progress Report.
Read the full announcement on the SET website ↗Financial Performance Quarter 3 (F45) (Reviewed)
Read the full announcement on the SET website ↗Management Discussion and Analysis Quarter 3 Ending 30 Sep 2026
Read the full announcement on the SET website ↗Financial Statement Quarter 3/2026 (Reviewed)
Read the full announcement on the SET website ↗Report on the results of the Exercise of XBIO-W8 (F53-5)
Read the full announcement on the SET website ↗Notification of the Amendment to the 2025 Annual Report ( Form 56-1 One Report )
Read the full announcement on the SET website ↗The Resignation and Appointment of Directors, Chief Executive Officer and Chief Financial Officer
Read the full announcement on the SET website ↗Notification the exercise of XBIO-W8
XBIO-W8 warrants can be exercised from 22-Oct-2026 to 29-Oct-2026, with an exercise date of 30-Oct-2026. The exercise price is 0.01567 baht per share, with an exercise ratio of 1 warrant to 2.55221 common shares.
Summarised automatically from the announcement filed with SET.
Read the full announcement on the SET website ↗Notification the final exercise and request for suspension of XBIO-W6
XBIO-W6 warrants have a final exercise date of 04-Jan-2027, with an exercise price of 0.69863 baht per share and an exercise ratio of 1 warrant to 2.14706 common shares. The exercise period is from 20-Dec-2026 to 03-Jan-2027. The stock will trade under a "SP" sign from 09-Dec-2026 to 04-Jan-2027, and the warrants will be delisted on 05-Jan-2027.
Summarised automatically from the announcement filed with SET.
Read the full announcement on the SET website ↗Report on the results of the Exercise of XBIO-W8 (F53-5)
No XBIO-W8 warrants were exercised during the exercise period from 30-Sep-2026 to 30-Sep-2026. The number of unexercised warrants is 222,349,082 units, with 567,481,189 shares remaining reserved.
Summarised automatically from the announcement filed with SET.
Read the full announcement on the SET website ↗Clarification of news or information requested by SET
X Biosciences Public Company Limited clarified to the Stock Exchange of Thailand regarding its financial statements for the second quarter of 2026. The company recognized a cumulative impairment loss of THB 270.63 million on its investment in Fruita Biomed Co., Ltd., due to the counterparty's liquidity constraints and Fruita's operating performance. The Board of Directors approved a revised share sale price of THB 110 per share and an extension of the transaction deadline to June 30, 2027. The company also addressed a THB 88 million short-term loan to a director of a subsidiary, noting corrective actions to ensure regulatory compliance.
Summarised automatically from the announcement filed with SET.
Read the full announcement on the SET website ↗Notification the exercise of XBIO-W8
XBIO-W8 warrants can be exercised from 23-Sep-2026 to 29-Sep-2026, with an exercise date of 30-Sep-2026. The exercise price is 0.01567 baht per share, and the exercise ratio is 1 warrant for 2.55221 common shares.
Summarised automatically from the announcement filed with SET.
Read the full announcement on the SET website ↗Report on the results of the Exercise of XBIO-W8 (F53-5) Revise (Revised)
XBIO-W8 warrants were exercised on 31-Aug-2026, with 10,000,000 units exercised. The exercise resulted in 25,522,100 new common shares at a price of 0.01567 baht per share. Unexercised warrants totaled 222,349,082 units, with 567,481,189 shares remaining reserved.
Summarised automatically from the announcement filed with SET.
Read the full announcement on the SET website ↗Report on the results of the Exercise of XBIO-W8 (F53-5)
XBIO-W8 warrants were exercised on 10,000,000 units from 24-Aug-2026 to 30-Aug-2026 at an exercise price of 0.01567 baht per share. The exercise resulted in 25,522,100 new common shares at a ratio of 1.00 warrant per 2.55221 shares. Unexercised warrants total 222,349,082 units, with 567,481,189 shares remaining reserved.
Summarised automatically from the announcement filed with SET.
Read the full announcement on the SET website ↗Financial Transaction with Risk to the Financial Position and Operating Performance. (Revised)
In Q2 2026, the company reported three financial transactions with risk. Item 1, an impairment of assets held for sale, involved a loss of 123,690.00 thousand baht, with rectification completed. Item 2, doubtful accounts, recorded a loss of 152,539.00 thousand baht and remains under rectification. Item 3, a loss on sale of assets, totaled 28,753.00 thousand baht, with rectification completed.
Summarised automatically from the announcement filed with SET.
Read the full announcement on the SET website ↗Financial Transaction with Risk to the Financial Position and Operating Performance.
The company reported asset impairment, allowance for doubtful accounts, expected credit loss, and write-off of assets totaling 507,554.00 thousand baht in Q2 2026. The loss amount represented 244.10% of operating income of 76,891.00 thousand baht and 643.60% of the net loss of (29,157.00) thousand baht for the quarter. The rectification has been completed.
Summarised automatically from the announcement filed with SET.
Read the full announcement on the SET website ↗Notification convening date of the Public Presentation
The company has scheduled an online public presentation for 28-Aug-2026 at 11:00. The objective is to provide information and a resolving plan for the events where shareholders' equity is < 50% of paid-up capital, and where the company has a loss for 3 consecutive years with shareholders' equity less than 100% of paid-up capital.
Summarised automatically from the announcement filed with SET.
Read the full announcement on the SET website ↗